Overall and Line-Specific Impact of Targeted Therapies in Advanced Biliary Tract Cancer After Chemoimmunotherapy Failure.

Matched targeted therapy after chemoimmunotherapy failure improves survival in advanced biliary tract cancer, especially when administered in second line, with median OS reaching 24.8 months.

• Why it matters: Understanding the optimal timing and access to targeted therapies is crucial because many patients with advanced biliary tract cancer do not benefit from current treatments, and early molecular profiling could expand effective options.
• What they did: The study analyzed 1,358 patients across multiple centers, performing molecular testing in 1,072 and identifying actionable alterations in 22.2%, with 32% receiving matched therapy, and compared outcomes between targeted and non-targeted treatments using advanced statistical methods.
• The result: Matched targeted therapy was linked to significantly longer overall survival and better response rates in second-line settings, emphasizing the importance of early molecular profiling and access to personalized treatments to improve patient outcomes.